Coagulation abnormalities after LPS/l-NAME treatment. (A) Consumptive coagulopathy 4.5 hours after administration of LPS and l-NAME. Recombinant hirudin (recHir) was administered to B6 mice at a dose of 225 ng/g at the same time as LPS. Data are derived from 3 to 6 mice per group (error bars = SEM). (B) Inhibition of phenotype in transgenic mice by titration with antifusion protein mAb. Inhibitory mAbs were injected at the same time as LPS. Each data point is from a single mouse. §Clauss fibrinogen assay was stopped at 20 minutes (5% or less normal mouse plasma fibrinogen) if no clot was observed; therefore, this value is minimum fibrinogen concentration detectable by this assay. *Comparing B6 plus LPS/l-NAME with either of the transgenic strains, P < .0001